- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study is testing a new eye treatment called JNJ-81201887 for a condition called Geographic Atrophy (GA). GA is a serious eye problem linked to ageing that can cause blurry vision. Researchers want to see if this new treatment can slow down the worsening of GA.
For: Geographic AtrophyNetherlands · Belgium · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
This study looks at a new gene therapy called Pariglasgene brecaparvovec for people with a rare liver condition called GSDIa. It aims to see if this new treatment can help reduce the amount of cornstarch they need to eat daily to keep their blood sugar stable.
For: Glycogen Storage Disease Type Ia (GSDIa)Denmark · Netherlands · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
For: Giant cell arteritis (GCA)Estonia · Sweden · Hungary